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Taking the guesswork out of supplying multi-compartment compliance aids: do pharmacists 1 
require further guidance on medication stability? 2 
As populations age, medications are increasingly being supplied to older individuals in different 3 
regions of the world, such as the United Kingdom and Australia, in medication organisers. These 4 
compliance aids organise medications according to dosage regimens, and may be referred to as multi-5 
compartment compliance aids (MCAs), monitored dosage systems (MDS) or dose administration aids 6 
(DAAs). However, these compliance aids are not air-tight, light resistant, or moisture-impermeable, 7 
and therefore light, humidity and temperature may adversely impact on medication stability.
[1]
 Patient 8 
risks of medication instability include: active ingredient degradation and loss of potency; changes in 9 
the formulation properties resulting in poor dissolution and poor absorption; adverse reactions from 10 
potentially toxic degradation product accumulation; and changes in physical appearance, potentially 11 
affecting patient adherence.
[2]
 Additionally, medication stability has not been a major focus of recent 12 
publications concerning MCAs, where medication repackaging incidents,
[3]
 or knowledge and 13 
adherence have been primarily explored. Of the published literature evaluating the stability of 14 
medications repackaged into MCAs, concerns regarding altered medication stability, bioavailability 15 
and patient acceptability have been raised. For example, 5mg prochlorperazine tablets stored for eight 16 
weeks in Multi-Dose Webster-Paks® and exposed to fluorescent lighting experienced discolouration, 17 
suggesting the presence of photodegradants that could potentially cause adverse effects.
[2]
 18 
Unacceptable variations in dissolution profiles (British Pharmacopoeia) and changes in weight, have 19 
been reported in 100mg sodium valproate tablets repackaged and stored in foil-backed, blister MCAs 20 
for 8 weeks at room temperature, refrigerated conditions, and accelerated conditions.
[1]
 Similarly, 21 
100mg generic atenolol tablets repackaged into 28 chamber plastic MCAs with transparent lids failed 22 
disintegration tests (British Pharmacopoeia) and dissolution tests (United States Pharmacopoeia) 23 
when stored for four weeks in accelerated conditions.
[4]
 The potential for non-equivalence between 24 
different types of MCAs has also been reported.
[5]
  Two different brands of 100mg generic atenolol 25 
tablet were repackaged for 4 weeks into two different plastic MCAs (Dosett® Maxi and Medidos®).
[5]
 26 
Three factors were tested with each of the two atenolol brands: temperature, MCA type, and co-27 
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storage with aspirin tablets.
[5]
 It was found that storage in MCAs impacted on the physical stability of 28 
atenolol at all conditions, where tablet hardness was affected more significantly in the Dosett® Maxi 29 
MCA compared to the Medidos® MCA.
[5]
 Further research examining the clinical significance of 30 
issues with medication stability when repackaged into MCAs is required. 31 
 32 
Pharmaceutical companies do not routinely provide information on the stability of medications 33 
repackaged into MCAs, as they are only obliged to submit data on long term and accelerated 34 
medication stability when stored in its original packaging. Church and Smith
[6]
 compiled information 35 
obtained from pharmaceutical manufacturers about the envisaged stability of medications repackaged 36 
into MCAs.  Interestingly, of the 392 medications investigated, none had undergone stability testing in 37 
MCAs.
[6]
 The following disclaimer was included alongside information provided by the 38 
pharmaceutical manufacturers, “It is important to note that the individual manufacturers do not 39 
endorse this practice of transferring medicines from the original packs to compliance aids as it may 40 
be outside the terms of their product licence. For the majority of manufacturers any information they 41 
provide is based on anecdotal evidence or in-house studies as no formal studies would have been 42 
carried out.”[6] A second disclaimer stated that, “The product information provided in this article has 43 
been provided by the marketing authorisation holders for these products. The marketing authorisation 44 
holders only recommend that their products are stored in accordance with the summary of product 45 
characteristics for each product and that storage of products in any other way is entirely at the 46 
pharmacist’s own risk.”[6] Additionally, there are limitations associated with the currency and breadth 47 
of information covered by resources that are designed to support pharmacists who provide MCAs. 48 
Those published in the United Kingdom and Australia, either have not been recently updated
[7]
 or do 49 
not provide a comprehensive list of medications that should not be repackaged.
[8]
 Additionally 50 
medication management guidelines may not specifically cover MCAs.
[9]
 51 
 52 
3 
 
These issues highlight a need for long-term solutions to ensure safe and effective use of MCAs, whilst 53 
in the shorter term attention can be paid to guidelines for practitioners to minimise potential problems. 54 
Several approaches to long-term solutions can be suggested. Firstly, pharmaceutical manufacturers 55 
could be advised to conduct medication stability tests with a specific focus on medications that are 56 
commonly repackaged, and which have existing stability concerns. Pharmaceutical analysis could be 57 
conducted in commonly used MCAs, such as pharmacy-supplied blister/bubble pack MCAs. This 58 
information could be included in medication product information. The feasibility of this suggestion 59 
would need to be explored as there are many different types of commonly used MCAs and some 60 
medications may already have guidance included in their product information. For example, the 61 
consumer medication information for hygroscopic sodium valproate (Epilim® and Valpro®) does not 62 
include information regarding medication stability in MCAs, however, the consumer medication 63 
information for thyroxine (Eutroxsig®) does. Secondly, pharmaceutical bodies could increase 64 
pharmacist awareness of evidence-based data from pharmaceutical manufacturers and academic 65 
research centres (who could themselves prioritise studies assessing medication stability), by regularly 66 
updating guidelines and databases with this information. Thirdly, the stability of medications 67 
repackaged into MCAs could be a topic of future continuing professional development events held by 68 
pharmaceutical bodies, to increase awareness of this issue amongst pharmacists and prescribers. 69 
Although pharmacists may be able to easily identify from original medication packaging or product 70 
information if stability issues are associated with medications they are handling. They may however 71 
not be aware of the potential adverse impacts of instability associated with repackaging medications 72 
into MCAs, they may consider that the benefits associated with MCAs outweigh the risks, or they 73 
may be unaware of alternative methods to supply these medications. It has been shown that some 74 
pharmacists repackage certain medications into MCAs, despite documented stability concerns. An 75 
Australian study examining the accuracy and suitability of repackaging medications into MCAs, 76 
supplied to 49 care homes, identified that the majority of inaccurate or unsuitable repackaging 77 
incidents involved repackaging potentially unstable medications, including sodium valproate.
[3]
 78 
Lastly, research and development targeted at improving how effectively MCAs can protect their 79 
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contents from air, light, humidity and temperature may be a beneficial long-term strategy to address 80 
the issue of medication instability when repackaged into MCAs.  81 
The benefits of MCAs may be considered to outweigh their risks and therefore, in the short term, 82 
pharmacists need to use their judgment when preparing MCAs, considering the professional and legal 83 
implications of this practice. This is important as the pharmaceutical manufacturer’s stability 84 
guarantee does not apply when medications are removed from their original packaging and stored in 85 
MCAs. When a licensed medication is used in a way that is not recommended by the manufacturer 86 
(outside its Marketing Authorisation) this is referred to as 'off-label' or 'off-licence' use. In such cases 87 
the prescriber should be made fully aware, as the prescriber and pharmacist then assume the 88 
responsibility for any associated risks e.g. adverse effects or potential treatment failure. Pharmacists 89 
and prescribers should also be supported by their professional organisations when making these 90 
decisions. Other recommendations that pharmacists may consider to ensure the optimal stability of 91 
medications supplied to patients include considering the product information, supplying medications 92 
in their original packaging, and adhering to available guidelines. Pharmacists can avoid repackaging 93 
medications that are moisture sensitive, such as effervescent
[8]
 and dispersible tablets;
[7]
 they can limit 94 
the time between removing medications from original packaging and placing them into MCAs;
[10]
 and 95 
alert patients to monitor MCA integrity and carefully remove tablets, preventing accidental rupture of 96 
nearby blisters and environmental exposure.
[10]
 Whilst MCAs are commonly prepared in 97 
environments of controlled temperature, they may be subsequently exposed to increased or 98 
uncontrolled temperature and humidity in-use.
[1]
 To address these concerns, it is recommended that 99 
medications should be stored in MCAs for no longer than eight weeks,
[8]
 in a cool, dry place, and 100 
protected from light. Research on in-use conditions should also be undertaken. 101 
 102 
Ultimately, decisions concerning the repackaging of medications into MCAs need to be informed by 103 
principles of pharmaceutical science, with more detailed and up to date guidance for prescribers and 104 
pharmacists, whilst working towards a stronger evidence-base for the use of these aids in the future. 105 
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